Hostname: page-component-586b7cd67f-gb8f7 Total loading time: 0 Render date: 2024-11-26T03:28:42.548Z Has data issue: false hasContentIssue false
  • English
  • Français

Clinical relevance of Paliperidone Palmitate three-month intramuscular injection formulation: an Italian Real-World, Retrospective, one-year Mirror Image Study

Published online by Cambridge University Press:  01 September 2022

S. Vanzetto ,
G. Cirnigliaro ,
V. Battini ,
E. Piccoli ,
M. Vismara ,
C. Viganò  and
B. Dell’Osso
S. Vanzetto*
Affiliation:
Luigi Sacco University Hospital, Psychiatry 2 Unit, ASST FBF-Sacco, University Of Milan, Milan, Italy
G. Cirnigliaro
Affiliation:
Luigi Sacco University Hospital, Psychiatry 2 Unit, ASST FBF-Sacco, University Of Milan, Milan, Italy
V. Battini
Affiliation:
Department of Clinical Pharmacology, ASST Fatebenefratelli-Sacco, University Of Milan, Milan, Italy
E. Piccoli
Affiliation:
Luigi Sacco University Hospital, Psychiatry 2 Unit, ASST FBF-Sacco, University Of Milan, Milan, Italy
M. Vismara
Affiliation:
Luigi Sacco University Hospital, Psychiatry 2 Unit, ASST FBF-Sacco, University Of Milan, Milan, Italy “Aldo Ravelli” Center for Nanotechnology and Neurostimulation”, University Of Milan, Milan, Italy
C. Viganò
Affiliation:
Luigi Sacco University Hospital, Psychiatry 2 Unit, ASST FBF-Sacco, University Of Milan, Milan, Italy
B. Dell’Osso
Affiliation:
Luigi Sacco University Hospital, Psychiatry 2 Unit, ASST FBF-Sacco, University Of Milan, Milan, Italy “Aldo Ravelli” Center for Nanotechnology and Neurostimulation”, University Of Milan, Milan, Italy Department of Psychiatry and Behavioral Sciences, Stanford University, Milan, Italy “Centro per lo studio dei meccanismi molecolari alla base delle patologie neuro-psico-geriatriche”, University Of Milan, Milan, Italy
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Paliperidone Palmitate 3-month (PP3M) formulation, introduced in Italy since 2017, is an effective and safety therapeutic option for patients with schizophrenia, clinically stable with 1-month formulation (PP1M). Only a few “Real World” studies investigated the clinical relevance of PP3M and the long-term clinical and health resource utilization outcomes.

Objectives

The aim of this retrospective, mirror image study was to evaluate the efficacy of PP3M in terms of continuity of care and number of hospitalizations.

Methods

Fifty outpatients treated with Paliperidone Palmitate (PP) were recruited from a Community Mental Health Centre (CMHC) in Milan. Statistical analysis were conducted with SPSS 26. Frequencies of hospitalization 6 months before and after the start of PP3M were compared using the McNemar test, setting the significance to p<0.05.

Results

This study involved 34 patients (68%) treated with PP1M and 16 (32%) treated with PP3M.The median time interval between PP1M and PP3M was 14 months. After the switch to PP3M, 69% of patients continued to visit the CMHC with an unchanged frequency (50% once/month, 6% more than once/month), while 31% with a decreased frequency (once/3 months). No patient increased the frequency of CMHC visits or started visiting it discontinuously. 44% of subjects had had at least one hospitalization prior to the switch and no hospitalizations after (p=0.016). Moreover, no patients showed increased hospitalizations

Conclusions

In this study PP3M clinical relevance was confirmed comparing pre-initiation and post-initiation 6-months time intervals: hospitalizations number significantly decreased, while the continuity of care was preserved. Further studies on a greater sample are necessary to support these preliminary data.

Disclosure

No significant relationships.

Keywords

one-year Mirror Image Studyclinical relevancepsychopharmacologyPaliperidone Palmitate 3-month formulation
Type
Abstract
Information
European Psychiatry , Volume 65 , Special Issue S1: Abstracts of the 30th European Congress of Psychiatry , June 2022 , pp. S346
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.